How Much Does Kerendia Cost?
The cost of Kerendia (finerenone) can vary depending on insurance coverage and pharmacy. Without insurance, a 30-day supply can range from approximately $500 to over $600 [1].
Can I Get Help Paying for Kerendia?
For eligible patients, Bayer, the manufacturer of Kerendia, offers a savings program. The Bayer Diabetes Care Savings Card can reduce out-of-pocket costs for commercially insured patients, potentially bringing the monthly cost down to as low as $10 [2]. Eligibility requirements and program details are available through the manufacturer.
What is Kerendia Used For?
Kerendia is a medication prescribed to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, kidney failure, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adults with chronic kidney disease (CKD) associated with type 2 diabetes [1].
How Does Kerendia Work?
Kerendia is a non-steroidal selective mineralocorticoid receptor antagonist [1]. It works by blocking the harmful effects of excess mineralocorticoid receptor stimulation in the kidneys and cardiovascular system, which can be exacerbated by type 2 diabetes [3]. This action helps to reduce inflammation and fibrosis, thereby protecting kidney and heart function [3].
When is Kerendia's Patent Expected to Expire?
Information regarding patent expiry dates for Kerendia is available through specialized resources like DrugPatentWatch.com [4].
Are There Other Treatments for CKD in Type 2 Diabetes?
Other treatment approaches for chronic kidney disease in type 2 diabetes may include blood sugar control, blood pressure management with ACE inhibitors or ARBs, SGLT2 inhibitors, and lifestyle modifications such as diet and exercise [3]. The choice of treatment depends on individual patient factors and medical history.
What Clinical Data Supports Kerendia's Use?
The efficacy and safety of Kerendia were evaluated in several clinical trials, including the FIDELITY program which comprises the FIDELIO-DKD and FIGARO-DKD studies. These studies demonstrated Kerendia's ability to reduce the risk of kidney and cardiovascular outcomes in patients with CKD and type 2 diabetes [1].
---
Sources:
[1] https://www.kerendia.com/
[2] https://www.kerendia.com/savings-and-support
[3] https://www.bayer.com/en/newsroom/press-releases/2021/bayer-announces-us-fda-approval-of-kerendia-finerenone-tablets-for-the-treatment-of-patients-with-chronic-kidney-disease-associated-with-type-2-diabetes
[4] https://drugpatentwatch.com/